HOB Biotech Group Corp.,Ltd (SHSE: 688656)
Health Care · Biotechnology · CN
CN¥101.78
+9.26% today · -18.8% 1Y
HOB Biotech Group Corp.,Ltd (SHSE: 688656) operates in the Biotechnology industry within the Health Care sector. The company is valued at $948.98M and employs 546 people.
Over the last twelve months the share price has lost 18.8%, trading between 76.62 and 217.00.
Tweenvest scores HOB Biotech Group Corp.,Ltd across four factors: quality 72/100, value 15/100, growth 13/100, dividend 11/100. Its strongest factor is quality.
688656 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $948.98M
- Revenue (TTM)
- $59.55M
- P/E
- 226.14
- EPS
- 0.45
- Dividend yield
- 0.20%
- Beta (5Y)
- -0.30
- 52-week high
- CN¥217.00
- 52-week low
- CN¥76.62
- Avg volume (3M)
- —
- Shares outstanding
- 62.68M
- Employees
- 546
- Next earnings
- —
About HOB Biotech Group Corp.,Ltd
HOB Biotech Group Corp.,Ltd. is an international in vitro diagnostics firm, active in both China and various global markets. It supplies advanced diagnostic assays, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immunoassays, to laboratories and hospitals. This endeavor aims to improve the treatment and care for patients afflicted with allergies and autoimmune diseases. The company was established in 2009 and is headquartered in Suzhou, China.
- ISIN
- CNE100004C37
- Founded
- 2009
- Listed since
- Jan 13, 2021
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.39 | +0.23% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.50 | -0.06% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $154.90 | -2.47% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.